2021
Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial
Chouairi F, Pacor J, Miller PE, Fuery MA, Caraballo C, Sen S, Leifer ES, Felker GM, Fiuzat M, O’Connor C, Januzzi JL, Friedman DJ, Desai NR, Ahmad T, Freeman JV. Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial. Mayo Clinic Proceedings Innovations Quality & Outcomes 2021, 5: 447-455. PMID: 33997640, PMCID: PMC8105522, DOI: 10.1016/j.mayocpiqo.2021.02.005.Peer-Reviewed Original ResearchNT-proBNP levelsReduced ejection fractionAtrial fibrillationHF hospitalizationHeart failureEjection fractionMedical therapyN-terminal pro-B-type natriuretic peptideOptimal guideline-directed medical therapyPro-B-type natriuretic peptideGuideline-directed medical therapyHigher NT-proBNP concentrationsHigher NT-proBNP levelsGUIDE-IT trialMedical therapy useHeart failure outcomesHeart Failure TrialPrevalent atrial fibrillationNT-proBNP concentrationsType natriuretic peptideEvidence-based therapiesCardiovascular deathAF patientsTherapy useFailure Trial
2013
Use of Evidence-based Cardiac Prevention Therapy Among Outpatients with Atrial Fibrillation
Hess PL, Kim S, Piccini JP, Allen LA, Ansell JE, Chang P, Freeman JV, Gersh BJ, Kowey PR, Mahaffey KW, Thomas L, Peterson ED, Fonarow GC. Use of Evidence-based Cardiac Prevention Therapy Among Outpatients with Atrial Fibrillation. The American Journal Of Medicine 2013, 126: 625-632.e1. PMID: 23787195, PMCID: PMC4037289, DOI: 10.1016/j.amjmed.2013.01.037.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntihypertensive AgentsAtrial FibrillationCardiovascular DiseasesComorbidityDefibrillators, ImplantableEvidence-Based PracticeFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLogistic ModelsMalePlatelet Aggregation InhibitorsPractice Guidelines as TopicRegistriesRisk FactorsConceptsCardiovascular comorbid conditionsEvidence-based therapiesAtrial fibrillationRisk factorsComorbid conditionsEvidence-based therapy useMore evidence-based therapiesGuideline-recommended therapiesAngiotensin receptor blockersAntiarrhythmic drug therapyCardiovascular risk factorsPeripheral vascular diseaseMinority of patientsCoronary artery diseaseMultivariable logistic regressionUS national registryAngiotensin-converting enzymeAldosterone antagonistsComorbid illnessesReceptor blockersComorbid diseasesAntiplatelet agentsArtery diseaseDiabetes mellitusHeart failure